Prerna Mewawalla, Myeloma and Transplant Physician, Associate Professor at Drexel University College of Medicine, shared a post on LinkedIn:
“Excited to share my latest interview with Cancer Network discussing the evolving role of FcRH5 targeted therapy in multiple myeloma and the potential of cevostamab to fill an important gap for patients who have progressed after BCMA and GPRC5D directed therapies.
Another exciting area is the emerging data for cevostamab post–CAR T-cell therapy, including deepening MRD-negative responses and the potential to help overcome resistance in heavily pretreated disease.
We are entering an era where sequencing and target diversification will become increasingly important in relapsed/refractory multiple myeloma.”
More posts featuring Prerna Mewawalla.